Patents matching “combination”

US 9951353

Engineering neural stem cells using homologous recombination

The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Apr 24, 2018 · Expires Apr 19, 2038

US 9943601

Etanercept formulations stabilized with combinations of sugars and polyols

Coherus BioSciences, Inc. · Granted Apr 17, 2018 · Expires Apr 12, 2038

US 9937192

Combination therapy to treat mycobacterium diseases

SPERO TRINEM, INC. · Granted Apr 10, 2018 · Expires Apr 5, 2038

US 9918989

Combination therapies for malaria

The Regents of the University of California · Granted Mar 20, 2018 · Expires Mar 15, 2038

US 9913822

Combination therapy with an anti-hyaluronan agent and therapeutic agent

HALOZYME, INC. · Granted Mar 13, 2018 · Expires Mar 8, 2038

US 9861621

LPT-723 and immune checkpoint inhibitor combinations and methods of treatment

Biomed Valley Discoveries, Inc. · Granted Jan 9, 2018 · Expires Jan 4, 2038

US 2018000900

COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

GANYMED PHARMACEUTICALS AG [DE] · Granted Jan 4, 2018 · Expires Dec 30, 2037

US 9855251

Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator

VTV THERAPEUTICS LLC · Granted Jan 2, 2018 · Expires Dec 28, 2037

US 9855305

Pharmaceutical composition containing combinations of vitamins, minerals, probiotics, and prebiotics effective in preventing adverse effects associated with the use of proton-pump inhibitors

Compass Therapeutics LLC · Granted Jan 2, 2018 · Expires Dec 28, 2037

US 9849167

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology · Granted Dec 26, 2017 · Expires Dec 21, 2037

US 9850542

Gene signature to predict homologous recombination (HR) deficient cancer

The Board of Regents of the University of Texas System · Granted Dec 26, 2017 · Expires Dec 21, 2037

US 9844540

Combination therapies for treating cancer

RedHill Biopharma Ltd. · Granted Dec 19, 2017 · Expires Dec 14, 2037

US 9839688

Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

Provectus Pharmatech, Inc. · Granted Dec 12, 2017 · Expires Dec 7, 2037

US 9820955

GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

The Regents of the University of California · Granted Nov 21, 2017 · Expires Nov 16, 2037

US 9808524

Combination of local and systemic immunomodulative therapies for melanoma and liver cancer

Provectus Pharmatech, Inc. · Granted Nov 7, 2017 · Expires Nov 2, 2037

US 9782437

Methods and compositions for targeted cleavage and recombination

Sangamo Therapeutics, Inc. · Granted Oct 10, 2017 · Expires Oct 5, 2037

US 9765147

Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Sep 19, 2017 · Expires Sep 14, 2037

US 9730989

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology · Granted Aug 15, 2017 · Expires Aug 10, 2037

US 9731011

Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

EnGeneIC Molecular Delivery Pty Ltd · Granted Aug 15, 2017 · Expires Aug 10, 2037

US 9700561

Drug combinations and uses in treating a coughing condition

Infirst Healthcare Limited · Granted Jul 11, 2017 · Expires Jul 6, 2037

US 9694071

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

TG Therapeutics, Inc. · Granted Jul 4, 2017 · Expires Jun 29, 2037

US 9675618

Drug combinations and uses in treating a coughing condition

Infirst Healthcare Limited · Granted Jun 13, 2017 · Expires Jun 8, 2037

US 2017136004

Opioid Agonist Antagonist Combinations

ALKERMES PHARMA IRELAND LTD [IE] · Granted May 18, 2017 · Expires May 13, 2037

US 9636334

Combination of lenalidomide and polypeptide construct, and uses thereof

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted May 2, 2017 · Expires Apr 27, 2037